RNAi reduces expression and intracellular retention of mutant cartilage oligomeric matrix protein

PLoS ONE

Volumn 5, Issue 4, 2010, Pages

  Posey, Karen L ^a   Liu, Peiman ^a   Wang, Huiqiu R ^a   Veerisetty, Alka C ^a   Alcorn, Joseph L ^a   Hecht, Jacqueline T ^a,b  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b Shriners Hospital for Children   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARTILAGE OLIGOMERIC MATRIX PROTEIN; MESSENGER RNA; SHORT HAIRPIN RNA; CARTILAGE MATRIX PROTEIN; GLYCOPROTEIN; MUTANT PROTEIN; SCLEROPROTEIN; SMALL INTERFERING RNA;

ANIMAL CELL; ARTICLE; BONE DYSPLASIA; CARTILAGE CELL; CELL CULTURE; CELL DEATH; CELL FUNCTION; CELL LINE; CULTURE TECHNIQUE; ENDOPLASMIC RETICULUM STRESS; GENE ACTIVITY; GENE MUTATION; GENETIC TRANSFECTION; GROWTH PLATE; HISTOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MOUSE; NONHUMAN; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; ANIMAL; CHONDRODYSPLASIA; GENETICS; METABOLISM;

MUS;

ANIMALS; CHONDROCYTES; EXTRACELLULAR MATRIX PROTEINS; GLYCOPROTEINS; MICE; MUTANT PROTEINS; OSTEOCHONDRODYSPLASIAS; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING;

EID: 77956410650     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0010302     Document Type: Article

References (59)

1. Adams JC, Tucker RP, Lawler J (1995) The thrombospondin gene family; Adams JC, ed. AustinTex., U.S.A.: R.G. Landes Co. 191 p.
2. Fang C, Johnson D, Leslie MP, Carlson CS, Robbins M, et al. (2001) Tissue distribution and measurement of cartilage oligomeric matrix protein in patients with magnetic resonance imaging-detected bone bruises after acute anterior cruciate ligament tears. J Orthop Res 19: 634-641.
3. Hecht JT, Deere M, Putnam E, Cole W, Vertel B, et al. (1998) Characterization of cartilage oligomeric matrix protein (COMP) in human normal and pseudoachondroplasia musculoskeletal tissues. Matrix Biol 17: 269-278.
4. Andersson ML, Thorstensson CA, Roos EM, Petersson IF, Heinegard D, et al. (2006) Serum levels of cartilage oligomeric matrix protein (COMP) increase temporarily after physical exercise in patients with knee osteoarthritis. BMC Musculoskelet Disord 7: 98.
5. Koelling S, Clauditz TS, Kaste M, Miosge N (2006) Cartilage oligomeric matrix protein is involved in human limb development and in the pathogenesis of osteoarthritis. Arthritis Research & Therapy 8: R56.
6. Briggs MD, Hoffman SM, King LM, Olsen AS, Mohrenweiser H, et al. (1995) Pseudoachondroplasia and multiple epiphyseal dysplasia due to mutations in the cartilage oligomeric matrix protein gene. Nature Genetics 10: 330-336.
7. Hecht JT, Nelson LD, Crowder E, Wang Y, Elder FF, et al. (1995) Mutations in exon 17B of cartilage oligomeric matrix protein (COMP) cause pseudoachon-droplasia. Nat Genet 10: 325-329.
8. Cooper RR, Ponseti IV, Maynard JA (1973) Pseudoachondroplastic dwarfism. A rough-surfaced endoplasmic reticulum storage disorder. Journal of Bone & Joint Surgery - American Volume 55: 475-484.
9. Merritt TM, Alcorn JL, Haynes R, Hecht JT (2006) Expression of mutant cartilage oligomeric matrix protein in human chondrocytes induces the pseudoachondroplasia phenotype. J Orthop Res 24: 700-707.
10. Merritt TM, Bick R, Poindexter BJ, Alcorn JL, Hecht JT (2007) Unique matrix structure in the rough endoplasmic reticulum cisternae of pseudoachondroplasia chondrocytes. Am J Pathol 170: 293-300.
11. Hecht JT, Makitie O, Hayes E, Haynes R, Susic M, et al. (2004) Chondrocyte cell death and intracellular distribution of COMP and type IX collagen in the pseudoachondroplasia growth plate. J Orthop Res 22: 759-767.
12. Xu C, Bailly-Maitre B, Reed JC (2005) Endoplasmic reticulum stress: cell life and death decisions. J Clin Invest 115: 2656-2664.
13. Chen TL, Posey KL, Hecht JT, Vertel BM (2008) COMP mutations: Domain-dependent relationship between abnormal chondrocyte trafficking and clinical PSACH and MED phenotypes. J Cell Biochem 103: 778-787.
14. Hecht JT, Hayes E, Haynes R, Cole WG (2005) COMP mutations, chondrocyte function and cartilage matrix. Matrix Biol 23: 525-533.
15. Diab M, Wu JJ, Eyre DR (1996) Collagen type IX from human cartilage: a structural profile of intermolecular cross-linking sites. Biochem J 314(Pt 1): 327-332.
16. Posey KL, Hankenson K, Veerisetty AC, Bornstein P, Lawler J, et al. (2008) Skeletal Abnormalities in Mice Lacking Extracellular Matrix Proteins, Thrombospondin-1, Thrombospondin-3, Thrombospondin-5, and Type IX Collagen. The American Journal of Pathology 172: 1664-1674.
17. Posey KL, Davies S, Bales ES, Haynes R, Sandell LJ, et al. (2005) In vivo human Cartilage oligomeric matrix protein (COMP) promoter activity. Matrix Biol 24: 539-549.
18. Thur J, Rosenberg K, Nitsche DP, Pihlajamaa T, Ala-Kokko L, et al. (2001) Mutations in cartilage oligomeric matrix protein causing pseudoachondroplasia and multiple epiphyseal dysplasia affect binding of calcium and collagen I, II, and IX. J Biol Chem 276: 6083-6092.
19. Kim SS, Peer D, Kumar P, Subramanya S, Wu H, et al. (2010) RNAi-mediated CCR5 silencing by LFA-1-targeted nanoparticles prevents HIV infection in BLT mice. Mol Ther 18: 370-376.
20. Vorhies JS, Nemunaitis JJ (2007) Nucleic acid aptamers for targeting of shRNA-based cancer therapeutics. Biologics 1: 367-376.
21. Xia CF, Boado RJ, Pardridge WM (2009) Antibody-mediated targeting of siRNA via the human insulin receptor using avidin-biotin technology. Mol Pharm 6: 747-751.
22. Takanashi M, Oikawa K, Sudo K, Tanaka M, Fujita K, et al. (2009) Therapeutic silencing of an endogenous gene by siRNA cream in an arthritis model mouse. Gene Ther 16: 982-989.
23. Davidson BL, Harper SQ (2005) Viral delivery of recombinant short hairpin RNAs. Methods Enzymol 392: 145-173.
24. Hecht JT, Hayes E, Snuggs M, Decker G, Montufar-Solis D, et al. (2001) Calreticulin, PDI, Grp94 and BiP chaperone proteins are associated with retained COMP in pseudoachondroplasia chondrocytes. Matrix Biol 20: 251-262.
25. Clark AG, Jordan JM, Vilim V, Renner JB, Dragomir AD, et al. (1999) Serum cartilage oligomeric matrix protein reflects osteoarthritis presence and severity: the Johnston County Osteoarthritis Project. Arthritis Rheum 42: 2356-2364.
26. DiCesare PE, Morgelin M, Carlson CS, Pasumarti S, Paulsson M (1995) Cartilage oligomeric matrix protein: isolation and characterization from human articular cartilage. J Orthop Res 13: 422-428.
27. DiCesare PE, Morgelin M, Mann K, Paulsson M (1994) Cartilage oligomeric matrix protein and thrombospondin 1. Purification from articular cartilage, electron microscopic structure, and chondrocyte binding. Eur J Biochem 223: 927-937.
28. Fang C, Carlson CS, Leslie MP, Tulli H, Stolerman E, et al. (2000) Molecular cloning, sequencing, and tissue and developmental expression of mouse cartilage oligomeric matrix protein (COMP). J Orthop Res 18: 593-603.
29. Perkins GL, Derfoul A, Ast A, Hall DJ (2005) An inhibitor of the stretch-activated cation receptor exerts a potent effect on chondrocyte phenotype. Differentiation 73: 199-211.
30. Briggs MD, Chapman KL (2002) Pseudoachondroplasia and multiple epiphyseal dysplasia: mutation review, molecular interactions, and genotype to phenotype correlations. Hum Mutat 19: 465-478.
31. Briggs MD, Mortier GR, Cole WG, King LM, Golik SS, et al. (1998) Diverse mutations in the gene for cartilage oligomeric matrix protein in the pseudoachondroplasia-multiple epiphyseal dysplasia disease spectrum. Am J Hum Genet 62: 311-319.
32. Deere M, Sanford T, Ferguson HL, Daniels K, Hecht JT (1998) Identification of twelve mutations in cartilage oligomeric matrix protein (COMP) in patients with pseudoachondroplasia. Am J Med Genet 80: 510-513.
33. Deere M, Sanford T, Francomano CA, Daniels K, Hecht JT (1999) Identification of nine novel mutations in cartilage oligomeric matrix protein in patients with pseudoachondroplasia and multiple epiphyseal dysplasia. Am J Med Genet 85: 486-490.
34. Unger S, Hecht JT (2001) Pseudoachondroplasia and multiple epiphyseal dysplasia: New etiologic developments. Am J Med Genet 106: 244-250.
35. Kleerekoper Q, Hecht JT, Putkey JA (2002) Disease-causing mutations in cartilage oligomeric matrix protein cause an unstructured Ca2+ binding domain. J Biol Chem 277: 10581-10589.
36. Hecht JT, Montufar-Solis D, Decker G, Lawler J, Daniels K, et al. (1998) Retention of cartilage oligomeric matrix protein (COMP) and cell death in redifferentiated pseudoachondroplasia chondrocytes. Matrix Biol 17: 625-633.
37. Posey KL, Hayes E, Haynes R, Hecht JT (2004) Role of TSP-5/COMP in Pseudoachondroplasia. Int J Biochem Cell Biol 36: 1005-1012.
38. Hashimoto Y, Tomiyama T, Yamano Y, Mori H (2003) Mutation (D472Y) in the type 3 repeat domain of cartilage oligomeric matrix protein affects its early vesicle trafficking in endoplasmic reticulum and induces apoptosis. Am J Pathol 163: 101-110.
39. Takahashi Y, Nishikawa M, Takakura Y (2008) Inhibition of tumor cell growth in the liver by RNA interference-mediated suppression of HIF-1alpha expression in tumor cells and hepatocytes. Gene Ther 15: 572-582.
40. Takeshita F, Hokaiwado N, Honma K, Banas A, Ochiya T (2009) Local and systemic delivery of siRNAs for oligonucleotide therapy. Methods Mol Biol 487: 83-92.
41. Zamora-Avila DE, Zapata-Benavides P, Franco-Molina MA, Saavedra-Alonso S, Trejo-Avila LM, et al. (2009) WT1 gene silencing by aerosol delivery of PEI-RNAi complexes inhibits B16-F10 lung metastases growth. Cancer Gene Ther.
42. Cashman SM, Bowman L, Christofferson J, Kumar-Singh R (2006) Inhibition of choroidal neovascularization by adenovirus-mediated delivery of short hairpin RNAs targeting VEGF as a potential therapy for AMD. Invest Ophthalmol Vis Sci 47: 3496-3504.
43. Eter N, Krohne TU, Holz FG (2006) New pharmacologic approaches to therapy for age-related macular degeneration. BioDrugs 20: 167-179.
44. Harper SQ, Staber PD, He X, Eliason SL, Martins IH, et al. (2005) RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc Natl Acad Sci U S A 102: 5820-5825.
45. Gonzalez-Alegre P, Bode N, Davidson BL, Paulson HL (2005) Silencing primary dystonia: lentiviral-mediated RNA interference therapy for DYT1 dystonia. J Neurosci 25: 10502-10509.
46. Suckau L, Fechner H, Chemaly E, Krohn S, Hadri L, et al. (2009) Long-term cardiac-targeted RNA interference for the treatment of heart failure restores cardiac function and reduces pathological hypertrophy. Circulation 119: 1241-1252.
47. Campbell TN, Choy FY (2004) Knockdown of chimeric glucocerebrosidase by green fluorescent protein-directed small interfering RNA. Genet Mol Res 3: 282-287.
48. Diaz-Font A, Chabas A, Grinberg D, Vilageliu L (2006) RNAi-mediated inhibition of the glucosylceramide synthase (GCS) gene: A preliminary study towards a therapeutic strategy for Gaucher disease and other glycosphingolipid storage diseases. Blood Cells Mol Dis 37: 197-203.
49. Pfeifer A, Eigenbrod S, Al-Khadra S, Hofmann A, Mitteregger G, et al. (2006) Lentivector-mediated RNAi efficiently suppresses prion protein and prolongs survival of scrapie-infected mice. J Clin Invest 116: 3204-3210.
50. Lopez-Fraga M, Wright N, Jimenez A (2008) RNA interference-based therapeutics: new strategies to fight infectious disease. Infect Disord Drug Targets 8: 262-273.
51. Christoph T, Gillen C, Mika J, Grunweller A, Schafer MK, et al. (2007) Antinociceptive effect of antisense oligonucleotides against the vanilloid receptor VR1/TRPV1. Neurochem Int 50: 281-290.
52. Bahi A, Boyer F, Kolira M, Dreyer JL (2005) In vivo gene silencing of CD81 by lentiviral expression of small interference RNAs suppresses cocaine-induced behaviour. J Neurochem 92: 1243-1255.
53. Kleinman ME, Yamada K, Takeda A, Chandrasekaran V, Nozaki M, et al. (2008) Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature 452: 591-597.
54. Whitehead KA, Langer R, Anderson DG (2009) Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov 8: 129-138.
55. Kappel S, Matthess Y, Zimmer B, Kaufmann M, Strebhardt K (2006) Tumor inhibition by genomically integrated inducible RNAi-cassettes. Nucleic Acids Res 34: 4527-4536.
56. Yoo JY, Kim JH, Kwon YG, Kim EC, Kim NK, et al. (2007) VEGF-specific short hairpin RNA-expressing oncolytic adenovirus elicits potent inhibition of angiogenesis and tumor growth. Mol Ther 15: 295-302.
57. Minakuchi Y, Takeshita F, Kosaka N, Sasaki H, Yamamoto Y, et al. (2004) Atelocollagen-mediated synthetic small interfering RNA delivery for effective gene silencing in vitro and in vivo. Nucleic Acids Res 32: e109.
58. Takeshita F, Minakuchi Y, Nagahara S, Honma K, Sasaki H, et al. (2005) Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. Proc Natl Acad Sci U S A 102: 12177-12182.
59. King KB, Kimura JH (2003) The establishment and characterization of an immortal cell line with a stable chondrocytic phenotype. J Cell Biochem 89: 992-1004.